New trials for prostate cancer

Enzalutamide for prostate cancer

May 2014

ANZUP and the CTC are collaborating with research groups around the world to conduct two of the largest clinical trials for sufferers of the world's most commonly diagnosed form of cancer, prostate cancer. The trials, ENZAMET and ENZARAD, aim to recruit 1900 men with prostate cancer in Australia, New Zealand, USA, Canada, UK, and Ireland.

Professor Ian Davis, Chair of ANZUP and Lead Investigator for the new global trials recently stated in the media that:

"the trials may provide opportunities to change the lives of prostate cancer sufferers around the world"

"These two trials aim to answer the basic questions that patients and their doctors face every day in the clinic: what is the best way of treating men with prostate cancer?"

"They will be two of the largest trials in prostate cancer and people around the world are already intensely interested in them and what their outcomes might be. These trials demonstrate once again that Australia punches above its weight in medical research." 

They involve a new hormone treatment, Enzalutamide, which is not currently approved in Australia for use in prostate cancer but has been shown to be effective in treating late stages of the disease.

The ENZAMET trial will involve about 1100 men with prostate cancer that has spread but has not yet been treated with hormones. 

The ENZARAD trial will include about 800 men with prostate cancer that has not spread and that is planned for treatment with radiotherapy. 

Astellas Scientific and Medical Affairs Inc. are providing Enzalutamide and financial support. The ENZAMET and ENZARAD trials are investigator-initiated and we encourage men with prostate cancer to seek further information from their general practitioner.

Read more about ENZARAD here. Read more about ENZAMET here.